A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Details
Age
Adult
Locations
Highlands Ranch Hospital
Lone Tree Medical Center
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Marie Wood
Study ID
Protocol Number: 23-1465
More information available at ClinicalTrials.gov: NCT05633654
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers